Chinese Abdominal tuina on metabolic sydrome patients with heat stagnation of liver and stomach sydrome: study protocol for a randomized parallel controlled trial

Introduction: The incidence of Metabolic Syndrome (MetS) continues to rise and has become a serious health hazard worldwide. Abdominal tuina treatment for MetS has the advantages of high safety and strong patient compliance, but there is still a lack of high-quality evidence-based medicine evidence.While,the study of the pathogenesis of MetS has progressed slowly, and its initiating factors are still unknown, so it is crucial to explore its mechanisms. Methods: and analysis This study was a randomized parallel controlled trial. One hundred and forty-four patients with metabolic sydrome patients with heat stagnation of liver and stomach sydrome were included, and the patients were randomly divided into a experimental group and a control group in a 1:1 ratio according to the random assignment principle, and the treatment course was 4 weeks in both groups. The control group was treated with conventional basic treatment based on lifestyle intervention; the experimental group was treated with abdominal massage (fifteen minutes) and acupoint pressure (thirty seconds/acupoint) on basis of the control group, 3 times/week, 12 times in total. Indicators were collected at different time points of the study, the results were analyzed and the safety was evaluated. Follow-up visits were performed 30 days after the end of the trial to assess the subjects' condition. The aim of this study was to evaluate the efficay and safety of abdominal tuina on the the early metabolic syndrome(MetS) patients with liver and stomach heat rentention type, and to provide new method and high quality evidence-based medical evidence for the prevention and treatment MetS.And to preliminary explore the action targets of abdominal tuina to improve MetS, provide theoretical basis for further mechanism exploration and direction for enriching the connotation of tuina theory. Trial registration ClinicalTrials.gov, ChiCTR2200057997, Registered on 26 March 2022.